Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment ...

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and hopes for future innovations.

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a ...

The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a ...

He shares that administering pembrolizumab (Keytruda; Merck) both before and after surgery, alongside adjuvant therapy, improves treatment responses and survival in patients with previously ...